Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: JoeinIowa who wrote (1147)	1/24/2003 12:02:46 PM
From: JoeinIowa	Respond to of 23958

Press Release Source: Alteon Inc. Alteon Inc. to Present at US Bancorp Piper Jaffray Healthcare Conference - Presentation to be Webcast - Friday January 24, 11:32 am ET RAMSEY, N.J., Jan. 24 /PRNewswire-FirstCall/ -- Alteon Inc. (Amex: ALT - News) announced today that Kenneth I. Moch, President and Chief Executive Officer, will be presenting at US Bancorp Piper Jaffray Healthcare Conference, Thursday, January 30, 2003, 12:00 p.m. ET, at The Pierre Hotel in New York City. Mr. Moch will give an overview of the recently announced positive results from the Phase 2a DIAMOND trial of ALT-711 in diastolic heart failure patients, as well as provide an update of corporate milestones for 2003. The presentation will be available to the general public via a live webcast, accessible at www.gotoanalysts.com/hccwebcast, and at the investor relations section of Alteon's website, www.alteon.com. About Alteon Alteon is developing several new classes of drugs that reverse or slow down diseases of aging and complications of diabetes. These compounds have an impact on a fundamental pathological process caused by protein-glucose complexes called Advanced Glycosylation End-products (A.G.E.s). The formation and crosslinking of A.G.E.s lead to a loss of flexibility and function in body tissues, organs and vessels and have been shown to be a causative factor in many age-related diseases and diabetic complications. Alteon is initially developing therapies for cardiovascular and kidney diseases in older or diabetic individuals. Alteon has created a library of novel classes of compounds targeting the A.G.E. Pathway. These include A.G.E. Crosslink Breakers, A.G.E. Formation Inhibitors and Glucose Lowering Agents. The Company's lead A.G.E. Crosslink Breaker, ALT-711, has demonstrated positive results in two Phase 2a trials, in cardiovascular compliance and in diastolic heart failure. The compound is currently being evaluated in the Phase 2b SAPPHIRE clinical trial focused on patients with systolic hypertension and the Phase 2b SILVER trial in patients with systolic hypertension and left ventricular hypertrophy, for which data will be reported concurrently about mid-year. Other A.G.E. compounds are being evaluated for skin aging and additional indications. For more information on Alteon, visit the Company's website at www.alteon.com.